[go: up one dir, main page]

AR035977A1 - Inmunoconjugados de anticuerpos cd44 citotoxicos. - Google Patents

Inmunoconjugados de anticuerpos cd44 citotoxicos.

Info

Publication number
AR035977A1
AR035977A1 ARP020101829A ARP020101829A AR035977A1 AR 035977 A1 AR035977 A1 AR 035977A1 AR P020101829 A ARP020101829 A AR P020101829A AR P020101829 A ARP020101829 A AR P020101829A AR 035977 A1 AR035977 A1 AR 035977A1
Authority
AR
Argentina
Prior art keywords
immunoconjugados
citotoxicos
antibodies
conjugates
antibody conjugates
Prior art date
Application number
ARP020101829A
Other languages
English (en)
Inventor
Adolf Guenther Dr
Patzelt Erik Dr
Sproll Marlies Dr
Heider Karl-Heinz Dr
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR035977A1 publication Critical patent/AR035977A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Conjugados de anticuerpos con compuestos citotóxicos, a composiciones farmacéuticas que contienen dichos conjugados, y a su uso en la terapia del cáncer. Conjugados de anticuerpos que son específicos para CD44, con maitansinoides, preferiblemente con N2'-desacetil-N2'-(3-mercapto-1-oxopropil)maitansina.
ARP020101829A 2001-05-18 2002-05-17 Inmunoconjugados de anticuerpos cd44 citotoxicos. AR035977A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01112227A EP1258255A1 (en) 2001-05-18 2001-05-18 Conjugates of an antibody to CD44 and a maytansinoid

Publications (1)

Publication Number Publication Date
AR035977A1 true AR035977A1 (es) 2004-07-28

Family

ID=8177473

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101829A AR035977A1 (es) 2001-05-18 2002-05-17 Inmunoconjugados de anticuerpos cd44 citotoxicos.

Country Status (24)

Country Link
EP (2) EP1258255A1 (es)
JP (1) JP2004529963A (es)
KR (1) KR20030097883A (es)
CN (1) CN1509187A (es)
AR (1) AR035977A1 (es)
BG (1) BG108366A (es)
BR (1) BR0209862A (es)
CA (1) CA2443438A1 (es)
CO (1) CO5550468A2 (es)
CZ (1) CZ20033477A3 (es)
EA (1) EA200301159A1 (es)
EE (1) EE200300568A (es)
HR (1) HRP20030932A2 (es)
HU (1) HUP0400046A3 (es)
IL (1) IL157965A0 (es)
MX (1) MXPA03010432A (es)
NO (1) NO20035108L (es)
NZ (1) NZ530167A (es)
PE (1) PE20021097A1 (es)
PL (1) PL365480A1 (es)
SK (1) SK15582003A3 (es)
WO (1) WO2002094325A2 (es)
YU (1) YU91503A (es)
ZA (1) ZA200307364B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071072B2 (en) * 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US6441163B1 (en) * 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
EP1417974A1 (en) * 2002-11-08 2004-05-12 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
DE10256083A1 (de) * 2002-11-29 2004-08-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Expressionsvektor, Verfahren zur Herstellung von heterologen Genprodukten und Selektionsverfahren für hochproduzierende rekombinante Zellen
US7384744B2 (en) 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
NZ542695A (en) * 2003-05-20 2009-04-30 Immunogen Inc Improved cytotoxic agents comprising new maytansinoids
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
ES2360403T3 (es) * 2003-07-21 2011-06-03 Immunogen, Inc. Conjugado citotóxico específico para el antígeno ca6 y métodos para usar el mismo.
US20050232919A1 (en) 2004-02-12 2005-10-20 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
ES2539126T3 (es) * 2004-12-09 2015-06-26 Janssen Biotech, Inc. Inmunoconjugados anti integrina, métodos para su producción y su uso
CA2597407C (en) * 2005-02-11 2013-09-10 Immunogen, Inc. Process for preparing stable drug conjugates
JP4949373B2 (ja) 2005-03-10 2012-06-06 モルフォテック、インク． 抗メソテリン抗体
ZA200708694B (en) * 2005-04-15 2009-01-28 Immunogen Inc Elimination of heterogeneous or mixed cell population in tumors
EP1879922A2 (en) 2005-04-22 2008-01-23 Morphotek, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
EP2662096A1 (en) * 2005-08-24 2013-11-13 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
AR059900A1 (es) * 2006-03-17 2008-05-07 Genentech Inc Anticuerpos anti-tat226 e inmunoconjugados
PT2437790T (pt) 2009-06-03 2019-06-04 Immunogen Inc Métodos de conjugação
UY32913A (es) * 2009-10-02 2011-04-29 Sanofi Aventis Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuero
CN107537040A (zh) 2011-03-29 2018-01-05 伊缪诺金公司 通过一步法制备类美登素抗体缀合物
CN102337298B (zh) * 2011-08-19 2013-11-06 黄开红 一种输送siRNA的免疫纳米载体及其制备方法和应用
AU2013326881B2 (en) 2012-10-04 2018-08-02 Immunogen, Inc. Use of a PVDF membrane to purify cell-binding agent cytotoxic agent conjugates
GB201220901D0 (en) * 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived peptides for treating pancreatic cancer
GB201220899D0 (en) * 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived pegylated peptides
GB201220891D0 (en) 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived peptides for treating breast cancers
GB201220889D0 (en) 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived peptides for treating metastasizing cancers
ES2996807T3 (en) 2013-03-15 2025-02-13 Regeneron Pharma Biologically active molecules, conjugates thereof, and therapeutic uses
WO2015031396A1 (en) 2013-08-26 2015-03-05 Regeneron Pharmaceuticals, Inc. Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
GB201421647D0 (en) 2014-12-05 2015-01-21 Amcure Gmbh And Ruprecht-Karls-Universitat And Karlsruher Institut F�R Technologie CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases
WO2016150521A1 (en) * 2015-03-26 2016-09-29 Fundación Imdea Nanociencia Functionalised magnetic nanoparticle
BR112017020149A8 (pt) 2015-03-27 2023-05-02 Regeneron Pharma Derivados de maitansinoide, conjugados dos mesmos e métodos de uso
US12098215B2 (en) 2016-06-06 2024-09-24 Northwestern University Fusion protein construct
CN112105643B (zh) * 2018-02-22 2023-09-26 普众发现医药科技(上海)有限公司 治疗性抗体及其应用
CN114057874B (zh) * 2020-07-31 2023-05-05 北京市神经外科研究所 抗cd44的单链抗体及其在制备治疗肿瘤的药物中的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) * 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
UY24389A1 (es) * 1995-12-06 2001-10-25 Karlsruhe Forschzent Composición farmacéutica para el tratamiento de carcinoma de epitelio plano
DE19648209A1 (de) * 1996-11-21 1998-05-28 Boehringer Ingelheim Int Verfahren zur Tumorzelldepletion CD34-positiver Zellen
DE19708713C2 (de) * 1997-03-04 2002-11-28 Boehringer Ingelheim Int Verwendung von anti-CD44 Antikörpern enthaltenden Präparationen zur Behandlung bestimmter Tumore und zur Unterdrückung von Immunreaktionen
HU230586B1 (hu) * 1999-06-25 2017-02-28 Genentech, Inc. Anti-ErbB antitest/maytansinoid konjugátumok alkalmazása rákos betegségek kezelésére szolgáló gyógyszer előállítására
EP2289549A3 (en) * 1999-10-01 2011-06-15 Immunogen, Inc. Immunoconjugates for treating cancer

Also Published As

Publication number Publication date
CO5550468A2 (es) 2005-08-31
EA200301159A1 (ru) 2004-06-24
CN1509187A (zh) 2004-06-30
EP1258255A1 (en) 2002-11-20
BG108366A (bg) 2004-09-30
PL365480A1 (en) 2005-01-10
CA2443438A1 (en) 2002-11-28
EP1395290A2 (en) 2004-03-10
HUP0400046A3 (en) 2006-02-28
HUP0400046A2 (hu) 2004-04-28
BR0209862A (pt) 2004-06-08
WO2002094325A2 (en) 2002-11-28
EE200300568A (et) 2004-04-15
WO2002094325A3 (en) 2003-04-17
SK15582003A3 (sk) 2004-04-06
HRP20030932A2 (en) 2004-04-30
IL157965A0 (en) 2004-03-28
MXPA03010432A (es) 2004-04-02
YU91503A (sh) 2006-05-25
ZA200307364B (en) 2004-04-20
CZ20033477A3 (en) 2004-05-12
NO20035108D0 (no) 2003-11-17
NZ530167A (en) 2005-10-28
NO20035108L (no) 2003-11-17
KR20030097883A (ko) 2003-12-31
PE20021097A1 (es) 2003-02-13
JP2004529963A (ja) 2004-09-30

Similar Documents

Publication Publication Date Title
AR035977A1 (es) Inmunoconjugados de anticuerpos cd44 citotoxicos.
DK1036058T3 (da) Adamantanderivater
DK1036059T3 (da) Adamantanderivater
CL2009002199A1 (es) Anticuerpo que se une especificamente a epitope de cripto; composicion farmaceutica que comprende dicho anticuerpo; uso del anticuerpo para disminuir el crecimiento de un tumor in vitro; metodo para modular el crecimiento de celulas de tumor in vitro en una muestra; anticuerpo humanizado (div. sol. n° 831-2002).
DE60142342D1 (de) Antikörper gegen doppelintegrinen, zusammensetzungen, verfahren und verwendungen
WO2004018000A3 (en) Compositions and methods for treating cancer using maytansinoid cd44 antibody immonoconjugates and chemotherapeutic agents
TR199802423T2 (xx) Konsantre antikor terkibi.
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
DE602006016344D1 (de) Für das fibroblastenaktivierungsprotein spezifische antikörpermoleküle und immunkonjugate, die diese enthalten
SE9704546D0 (sv) Novel compounds
CY1112687T1 (el) Μεθοδος για χρηση δικετοπιπεραζινων και συνθεσεις που περιλαμβανουν αυτες
BR0210568A (pt) Conjugado, uso de um conjugado, composição farmacêutica, e, método para tratar câncer em um mamìfero
CY1111863T1 (el) Αντισωματα εναντιον υποδοχεα θανατου 4 (dr4) και χρησεις αυτων
ATE389721T1 (de) Agonistische antikörper gegen den thrombopoietinrezeptor und deren therapeutische verwendungen
TR200001218T2 (tr) İkameli karboksamidotiazoller, bunların üretimi ve bunları içeren farmasötik bileşimler.
EP1423107A4 (en) FATTY ALCOHOL DRUG CONJUGATES
TR200100054T2 (tr) Paroksetin metansülfonat
BR9608488A (pt) Uso de derivados da vitamina d4 no tratamento de câncer
DE60113445D1 (de) Substanzen mit verzweigten linkermolekülen
SE9802937D0 (sv) Novel compounds
EE200100366A (et) Antikehade kasutamine vähivastase farmatseutilisekompositsiooni valmistamiseks
DE60141297D1 (de) Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
WO2002066492A3 (fr) Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques.
UY27291A1 (es) Inmunoconjugados de anticuerpos cd44 citotóxicos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal